IBRX
Another day, another securities lawsuit
Faruqi & Faruqi says investors who bought ImmunityBio shares between January 19 and March 24, 2026 may have claims in a federal class action, and the firm is pushing a May 26 lead-plaintiff deadline. In plain English: if you were holding the bag during that stretch, the legal clock is now ticking.
What’s the beef?
The complaint, according to the firm, says ImmunityBio and its executives made false or misleading claims about the company’s prospects. The big accusation centers on Patrick Soon-Shiong allegedly overstating Anktiva’s capabilities — which is a pretty bad look when your whole story depends on the drug doing heavy lifting.
Why investors should care
This isn’t about a shiny new product or a surprise revenue beat. It’s about the kind of legal cloud that can hang over a stock and make every earnings call feel like it’s being cross-examined.
The article also points back to ImmunityBio’s January 23 press release on updated Phase 2 results from QUILT 3.078 in glioblastoma, where median overall survival had “not yet been reached.” That’s the sort of clinical phrasing that can sound thrilling in a headline and messy in a courtroom.
Big picture
For now, this is headline risk more than business-model risk — but in biotech, those two can get uncomfortably cozy. If the lawsuit gains traction, IBRX could be dealing with more than just a rough patch in the lab.